Bachem whitepaper shows Conjugation Chemistry routes to unlock oligomer-based therapies

The latest whitepaper from Leading CDMO Bachem AG details how conjugation chemistry processes can transform the application potential of oligonucleotides.

The Bachem technical bulletin ‘Conjugation Chemistry: Improving Oligonucleotide Targeted Delivery’ is available for immediate reading online or download below.

Unlocking oligomer-based therapies

Oligonucleotides are emerging as a powerful new class of therapeutics that show promise as groundbreaking new therapies. More than 700 oligomer-based drugs are in the pharmaceutical pipeline with several already at the clinical trial stage.

Oligonucleotide therapies are particularly exciting because their highly targeted nature offers patients novel transformative treatments for conditions previously regarded as untreatable. However, to make this a reality, it has become apparent drug manufacturers first of all have to contend with oligonucleotides’ poor pharmacokinetics and pharmacodynamics.

Addressing specific oligo issues

Issues such as tissue targeting, cellular uptake, tolerability and stability all need to be addressed when designing oligonucleotide therapeutics. Chemical modifications and conjugation to a variety of molecules can help overcome these challenges, with peptide conjugation emerging as a promising approach that is explored in this whitepaper.

The latest guide adds to a suite of Bachem scientific tools, including a series of tide-related blogs, webinars, and technical papers.

Resources

Click on Bachems News to see latest News & Events.